Quick Answer Acrivon Therapeutics, Inc. reported Cash and Equivalents of $41.50 million for fiscal year 2025. Acrivon Therapeutics, Inc. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $41.50M +4.2% 2024 $39.82M +10.6% 2023 $36.02M +22.0% 2022 $29.52M -70.4% 2021 $99.60M — Quarterly Cash and Equivalents Quarter Ending Cash and … Read more
Quick Answer Acrivon Therapeutics, Inc. reported Total Assets of $129.72 million for fiscal year 2025. Acrivon Therapeutics, Inc. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $129.72M -34.0% 2024 $196.59M +42.2% 2023 $138.26M -23.7% 2022 $181.23M +70.0% 2021 $106.59M — Quarterly Total Assets Quarter Ending Total Assets YoY QoQ September 30, … Read more
Quick Answer Acrivon Therapeutics, Inc. reported Net Income of -$77.91 million for fiscal year 2025. Acrivon Therapeutics, Inc. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$77.91M +3.3% 2024 -$80.56M -33.4% 2023 -$60.39M -93.8% 2022 -$31.17M -91.9% 2021 -$16.24M — Quarterly Net Income Quarter Ending Net Income YoY QoQ September 30, … Read more
Quick Answer Acrivon Therapeutics, Inc. reported Diluted EPS of $2.02 per share (loss) for fiscal year 2025. Acrivon Therapeutics, Inc. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 -$2.02 +15.1% 2024 -$2.38 +13.1% 2023 -$2.74 +63.8% 2022 -$7.56 +18.9% 2021 -$9.32 — Quarterly Diluted EPS Quarter Ending Diluted EPS YoY QoQ … Read more
Quick Answer Acrivon Therapeutics, Inc. reported Net Income of -$77.91 million for fiscal year 2025. Acrivon Therapeutics, Inc. — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Net Income -$77.91M+3.3% -$80.56M-33.4% -$60.39M-93.8% -$31.17M-91.9% -$16.24M — Diluted EPS -$2.02+15.1% -$2.38+13.1% -$2.74+63.8% -$7.56+18.9% -$9.32 — Total Assets $129.72M-34.0% $196.59M+42.2% $138.26M-23.7% $181.23M+70.0% $106.59M — Cash … Read more
Quick Answer Aclaris Therapeutics, Inc. reported Shares Outstanding of 120.50 million shares for fiscal year 2025. Aclaris Therapeutics, Inc. Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 120.50M +11.7% 2024 107.85M +52.1% 2023 70.89M +6.3% 2022 66.69M +8.9% 2021 61.23M +35.7% 2020 45.11M +8.7% 2019 41.49M +0.7% 2018 41.21M +33.6% 2017 … Read more
Quick Answer Aclaris Therapeutics, Inc. reported Gross Profit of $3.24 million for fiscal year 2018. Aclaris Therapeutics, Inc. Gross Profit — Annual History Fiscal Year Gross Profit YoY Change 2018 $3.24M +580.9% 2017 $476.0K — Quarterly Gross Profit Quarter Ending Gross Profit YoY QoQ September 30, 2018 $435.0K +88.3% -82.6% June 30, 2018 $2.50M — … Read more
Quick Answer Aclaris Therapeutics, Inc. reported Operating Income of -$76.38 million for fiscal year 2025. Aclaris Therapeutics, Inc. Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 -$76.38M +46.2% 2024 -$141.93M -45.8% 2023 -$97.36M -8.4% 2022 -$89.85M -0.1% 2021 -$89.72M -76.2% 2020 -$50.91M +54.2% 2019 -$111.06M -31.0% 2018 -$84.78M -56.0% 2017 -$54.36M … Read more
Quick Answer Aclaris Therapeutics, Inc. reported R&D Expense of $52.65 million for fiscal year 2025. Aclaris Therapeutics, Inc. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $52.65M +56.7% 2024 $33.59M -65.9% 2023 $98.38M +26.4% 2022 $77.81M +77.6% 2021 $43.81M +49.3% 2020 $29.34M -54.3% 2019 $64.17M +5.5% 2018 $60.84M +69.9% 2017 $35.80M … Read more
Quick Answer Aclaris Therapeutics, Inc. reported Long-Term Debt of $10.65 million for fiscal year 2020. Aclaris Therapeutics, Inc. Long-Term Debt — Annual History Fiscal Year Long-Term Debt YoY Change 2020 $10.65M -64.4% 2018 $29.91M — Quarterly Long-Term Debt Quarter Ending Long-Term Debt YoY QoQ June 30, 2021 $10.73M +1.5% +0.4% March 31, 2021 $10.69M +1.1% … Read more